Combined bacterial and viral treatment: a novel anticancer strategy

Marcin P. Krzykawski

doi:10.5114/ceji.2015.54601

eISSN: 1644-4124
ISSN: 1426-3912

Central European Journal of Immunology

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

3/2015
vol. 40

Send email

Copy url:

abstract:

Review paper

Combined bacterial and viral treatment: a novel anticancer strategy

Marcin P. Krzykawski

(Centr Eur J Immunol 2015; 40 (3): 366-372)

DOI: https://doi.org/10.5114/ceji.2015.54601

Online publish date: 2015/10/15

View full text Get citation

PlumX metrics:

An idea for a new combination therapy will be described herein. It is a proposition to combine viral and bacterial anticancer therapies and make them fight cancer in concert. We analyzed biological anticancer therapies and found overlapping advantages and disadvantages which led us to the conclusion that the combination therapy has the potential to create a new therapeutic quality. It is surprising how many weaknesses of viral anticancer therapy are the strengths of bacterial anticancer therapies and the other way round. We review the facts behind this concept and try to assess its value. We propose a few strategies how to combine these two therapies but as far as the review can go, final answers will have to come from the experiments. This review is the first attempt to describe a new strategy and understand the means for this idea but also to raise new questions and discuss new ways to look at anti-cancer treatment.

keywords:

Combined bacterial and viral treatment: a novel anticancer strategy

Marcin P. Krzykawski

oncolytic bacteria, oncolytic viruses, anticancer therapy